Evidence map›Paper›PMID 39005274›Full record

ArticlebioRxiv : the preprint server for biology2024

"Target-and-release" nanoparticles for effective immunotherapy of metastatic ovarian cancer.

Ivan S Pires, Gil Covarrubias, Victoria F Gomerdinger, Coralie Backlund, Apoorv Shanker, Ezra Gordon, Shengwei Wu, Andrew J Pickering, Mariane B Melo, Heikyung Suh and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ivan S PiresKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.ORCID 0000-0002-4035-0027
Gil CovarrubiasKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Victoria F GomerdingerKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Coralie BacklundKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Apoorv ShankerKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Ezra GordonDepartment of Chemical Engineering, MIT, Cambridge, MA 02139, USA.
Shengwei WuKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Andrew J PickeringKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Mariane B MeloKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Heikyung SuhKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Paula T HammondKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.ORCID 0000-0002-9835-192X

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticlesR01CA235375 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond, Darrell J Irvine · 2019 to 2026
$2.3M
Engineering Next-Generation Nanoparticles One Layer at a TimeF99CA274651 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SUSIN PIRES, IVAN · 2022 to 2023
$96k
NCI NIH HHS F99 CA274651NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA235375
6 · The paper itself

Abstract

Immunotherapies such as checkpoint inhibitors (CPI) are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer (OC). Here, we engineered liposomal nanoparticles (NPs) carrying a layer-by-layer (LbL) polymer coating that promotes their binding to the surface of OC cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the LbL particles to concentrate IL-12 in disseminated OC tumors following intraperitoneal administration. Shedding of the LbL coating and serum protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in the tumor bed following rapid NP localization in tumor nodules. Optimized IL-12 LbL-NPs promoted robust T cell accumulation in ascites and tumors in mouse models, extending survival compared to free IL-12 and remarkedly sensitizing tumors to CPI, leading to curative treatments and immune memory.

Indexed as

immunotherapyinterleukin-12layer-by-layernanoparticlesovarian cancer

Identifiers

PMID39005274
PMCPMC11245112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.